Skip to content

Effectiveness of Preemptive Administration of Oliceridine in Reducing Postoperative Acute Pain in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized, Double-Blind Controlled Study

Effectiveness of Preemptive Administration of Oliceridine in Reducing Postoperative Acute Pain in Patients Undergoing Laparoscopic Cholecystectomy: A Randomized, Double-Blind Controlled Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400092308
Enrollment
Unknown
Registered
2024-11-14
Start date
2024-11-15
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postoperative pain

Interventions

O group: Oliceridine Group:Oliceridine 2mg
D Group: Dezocine Group:Dezocine 10mg
N Group :Normal saline Group:Normal saline 10ml

Sponsors

Chengdu Pidu District People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Ages 18 to 65 years old , gender not specified; 2. Patients are willing and able to provide signed informed consent before any study-related procedures. 3. Elective surgery patients who are scheduled to undergo laparoscopic cholecystectomy under general anesthesia.

Exclusion criteria

Exclusion criteria: 1. Combined respiratory diseases (such as asthma, COPD); 2. Combined intestinal obstruction; 3. ECG indicating prolonged QTc interval; 4. History of analgesic drug abuse; 5. Cognitive impairment; 6. Patients unable to communicate; 7. Women who are pregnant or breastfeeding; 8. Undergoing additional surgical procedures concurrent with or within 24 hours of cholecystectomy.

Design outcomes

Primary

MeasureTime frame
Incidence of moderate to severe pain;

Secondary

MeasureTime frame
Incidence of moderate to severe pain;The dosage of intraoperative analgesics and anesthetics used;The frequency of remedial analgesia and the dosage of analgesic drugs used;Nausea and vomiting incidence rate;Blood sugar level;Neutrophil to lymphocyte ratio;

Countries

China

Contacts

Public ContactLi Junxiang

Chengdu Pidu District People's Hospital

494973600@qq.com+86 183 4930 1952

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026